Geriatrics
Conference Coverage
Intepirdine flops in phase 3 study of mild to moderate Alzheimer’s patients
BOSTON – But investigation continues in a phase 3 placebo-controlled study in patients with Lewy body dementia.
News
MACRA Monday: Elder maltreatment screening
Screen an elderly patient for maltreatment and document a follow-up plan, if appropriate, and you could avoid a 4% MIPS penalty.
Conference Coverage
Long-term cholinesterase inhibition may slow cognitive decline – and more
BOSTON – New data suggest the drugs also reduce risk of heart attack, stroke, and all-cause mortality.
Conference Coverage
Pimavanserin found modestly effective in phase 2 Alzheimer’s psychosis study
BOSTON – The drug’s small improvement in psychotic symptoms may take weeks to appear, but its effect seemed to spare cognition.
Conference Coverage
Unblinded data show extent of verubecestat’s failure in mild-moderate Alzheimer’s
BOSTON – No benefit was seen in any endpoint, in any subgroup.
Conference Coverage
Amyloid imaging changed management for 80% of patients with uncertain dementia diagnosis
BOSTON – Amyloid imaging can alleviate many of the difficulties in diagnosing some cases of dementia, and using florbetaben looks especially...
Conference Coverage
New BACE1 study launches in the shadow of verubecestat’s demise
An ambitious new clinical trial will investigate a different BACE-inhibiting molecule as an Alzheimer’s preventive in people at high genetic risk...
Conference Coverage
Nebulized glycopyrrolate improves lung function in COPD
TORONTO – Glycopyrrolate, a novel nebulized long-acting muscarinic antagonist (LAMA) in development, was well-tolerated and significantly improved...
Conference Coverage
Aducanumab continues to rack up positive numbers in phase 1b open-label extension
BOSTON – Data at 3 years support the relative safety of aducanumab in patients with prodromal or mild Alzheimer’s.
Conference Coverage
Analysis of failed Alzheimer’s trials gives two antiamyloid antibodies new momentum
BOSTON – Researchers are increasing the doses of two antiamyloid drugs in new and existing Alzheimer’s trials based on data from extension studies...
Applied Evidence
What’s causing my older patient’s cognitive decline?
Changes related to aging alone typically don’t interfere with one’s ability to function independently. These tips and tools can help ensure an...